You are here: Welcome » PAXLOVID™ (PF-07321332; ritonavir)

Differences

This shows you the differences between two versions of the page.

Link to this comparison view

Both sides previous revisionPrevious revision
Next revision		Previous revision
Both sides next revision
paxlovid [2022/02/03 22:09]
brian [In the News] 		paxlovid [2022/08/27 12:52] (current)
mathew
Line 22: Line 22:
 || NCT05129475 | Food Effect Study to Evaluate the Effect of High-Fat Meal on the Relative Bioavailability of PF-07321332 Boosted With Ritonavir in Healthy Adult Participants || || NCT05129475 | Food Effect Study to Evaluate the Effect of High-Fat Meal on the Relative Bioavailability of PF-07321332 Boosted With Ritonavir in Healthy Adult Participants ||
 || NCT05064800 | PF-07321332/Ritonavir and Ritonavir on Dabigatran Study in Healthy Participants || || NCT05064800 | PF-07321332/Ritonavir and Ritonavir on Dabigatran Study in Healthy Participants ||
 +
 +==== Press Releases ====
 +On Friday, November 5, 2021, Pfizer issued a stunningly optimistic press release for a new drug, stating "overwhelming efficacy" and a risk reduction of 89% for hospitalization and death from COVID-19.((November 5, 2021 | Pfizer | [[https://www.pfizer.com/news/press-release/press-release-detail/pfizers-novel-covid-19-oral-antiviral-treatment-candidate|Pfizer’s Novel COVID-19 Oral Antiviral Treatment Candidate Reduced Risk of Hospitalization or Death by 89% in Interim Analysis of Phase 2/3 EPIC-HR Study]])) The press release claimed that after 28 days there were 0 deaths in the treatment arm and 10 in the placebo arm, with 41 vs. 6 hospitalizations.
  
  
Back to top